Shanghai Kai Kai Industry Company Limited (SHSE:600272) shares have had a horrible month, losing 27% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year’s worth of gains with the share price now back where it started a year ago.
Although its price has dipped substantially, there still wouldn’t be many who think Shanghai Kai Kai Industry’s price-to-sales (or “P/S”) ratio of 3.1x is worth a mention when the median P/S in China’s Pharmaceuticals industry is similar at about 3.4x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
View our latest analysis for Shanghai Kai Kai Industry
What Does Shanghai Kai Kai Industry’s P/S Mean For Shareholders?
For instance, Shanghai Kai Kai Industry’s receding revenue in recent times would have to be…
